Trial is underway for childrens’ COVID vaccine in Cuba

The head of the Centre for State Control of Medicines, Equipment and Medical Devices - CECMED, has informed that a clinical trial on a COVID-19 vaccination is competently underway in Cuba.

Cuba: The head of the Centre for State Control of Medicines, Equipment and Medical Devices – CECMED, has informed that a clinical trial on a COVID-19 vaccination is competently underway in Cuba.

Dr Meiby de la Caridad Rodríguez González, asserted that the first anti-COVID-19 research in children and adolescents assembled with an austere approval process seven weeks after the case study was submitted to the supervisory authority.

The first inspection was held on 14 June 2021, when the first dose of the COVID-19 vaccine was administered. The first and second trial phase of the Soberana-Pediatrics vaccine includes children and adolescents in between the age of 3 to 18 years of Cuban nationality.

A total of 50 individuals volunteered for the first phase trial, while 300 volunteered for the second phase trial. The Health Officials have informed that the trial would take place in a sequence.

Rodríguez González further stated, “After the first week of immunisation, blood tests would be performed to ascertain the safety of the vaccine, to request the approval of CECMED to continue with the group from 3 to 11 years of age and to continue towards phase II with a larger number of adolescents.”

Following the statement, Rodríguez González asserted that the first stage of the study would take place at the Juan Manuel Márquez Pediatric Hospital, and later the vaccine trial would be extended to the health areas of the municipalities of Playa, Marianao and La Lisa.

The island has decided to rely upon the homemade vaccines on which the President of Cuba – Miguel Diaz-Canel, stated, “We know the government has not been able to provide this project all the funding it required, and nevertheless this is a result of global standing.”

Currently, there are five vaccine applicants in clinical trials in Cuba; one of those is Soberana 2 vaccine. The Soberana 2 vaccine, which is produced by the state-run Finlay Vaccine Institute, has shown a 62 per cent efficacy rate in just two doses out of three.